Litigation Details for TAKEDA PHARMACEUTICALS AMERICA, INC. v. APOTEX, INC. (D.N.J. 2021)
✉ Email this page to a colleague
TAKEDA PHARMACEUTICALS AMERICA, INC. v. APOTEX, INC. (D.N.J. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-06-25 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Kevin McNulty |
| Jury Demand | None | Referred To | |
| Patents | 8,114,874; 9,493,470 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in TAKEDA PHARMACEUTICALS AMERICA, INC. v. APOTEX, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for TAKEDA PHARMACEUTICALS AMERICA, INC. v. APOTEX, INC. (D.N.J. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-01-12 | 119 | Opinion | include nonhuman 12 Zou et al., U.S. Patent No. 8,114,874 (DE 64-5). …The patents-in-suit are Patent Nos. 9,493,470 (the “’470 patent”), 11,192,895 (the “’895 patent”), 11,192,897… 63) ’470 Patent = Patent No. 9,493,470 (DE 63-2) ’895 Patent = Patent No. 11,192,895 (DE…,192,897 (the “’897 patent”), and 11,384,086 (the “’086 patent”).1 These patents are directed to crystalline…, and ’897 patents—was consolidated with Civil Action No. 1:22-cv-06151, a parallel patent infringement | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
